Results 21 to 30 of about 186,975 (294)

Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study

Endocrine Journal, 2023
CA19-9 is a tumor marker for pancreatic cancer (PC), and the nondiabetic cut-off level is 37 U/mL. CA19-9 levels are said to rise in patients with tumors like PC and intraductal papillary mucinous neoplasm (IPMN). CA19-9 levels have also been shown to be
Taku Yamada, Taichi Minami, Masayo Yamada, Yasuo Terauchi   +3 more
doaj   +1 more source

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer [PDF]

, 2006
In pancreatic cancer ( PC) accurate determination of treatment response by imaging often remains difficult. Various efforts have been undertaken to investigate new factors which may serve as more appropriate surrogate parameters of treatment efficacy ...
Anderson JS, Bekaii-Saab TS, Brambs HJ, Burris HA, Ebrahimi B, Glenn J, Gogas H, Goggins M, Heinemann V, Heinemann V, Heinemann V, Ishii H, Jamieson NB, Jiang XT, Katz A, Ko AH, Koprowski H, Louvet C, Lundin J, Maisey NR, Montgomery RC, Moore MJ, Ni XG, Okusaka T, Petra Stieber, Philip PA, Ralf Wilkowski, Saad ED, Safi F, Safi F, Sakar B, Sawaki A, Sperti C, Stathopoulos GP, Stefan Boeck, Stefan Holdenrieder, Steinberg W, Tanaka N, Tempero MA, Tian F, van Custem E, Vimalachandran D, Volker Heinemann, Wilkowski R, Wilkowski R, Wilkowski R, Willet CG, Wolff RA, Ziske C   +48 more
core   +1 more source

Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: Pretreatment levels or kinetics during chemotherapy? [PDF]

, 2007
Background: The carbohydrate antigen 19-9 (CA 19-9) is currently the most widely used serum tumor marker in pancreatic cancer (PC). CA 19-9 pretreatment levels as well as CA 19-9 kinetics during systemic chemotherapy can provide prognostic information ...
Boeck, Stefan, Heinemann, Volker, Holdenrieder, Stefan, Schulz, Christoph, Stieber, Petra, Weckbach, Sabine   +5 more
core   +1 more source

Reactivity of CA19-9 and CA125 in Histological Subtypes of Epithelial Ovarian Tumors and Ovarian Endometriosis [PDF]

, 2015
Previous reports have shown that some ovarian endometrioid adenocarcinomas and ovarian clear cell adenocarcinomas derive from ovarian endometriosis (OE), and that endocervical-like mucinous borderline ovarian tumors are associated with OE.
Hasegawa, Masaaki, Hashimoto, Toru, Kataoka, Mikio, Koda, Hiromi, Nakagawa, Naohisa, Nakahara, Yukie, Nakahori, Takashi, Nitta, Noriko, Uno, Jiro   +8 more
core   +1 more source

Carbohydrate antigen 19‐9 is extremely elevated in polycystic liver disease [PDF]

Liver International, 2009
AbstractBackground/Aims: Carbohydrate antigen 19‐9 (CA19‐9) is used as a biomarker to differentiate benign from malignant gastrointestinal disorders. We examined the value of CA19‐9 measurement in polycystic livers after observing high CA19‐9 cyst fluid levels in a benign polycystic liver case.Methods: We determined CA19‐9 levels in serum (n=120) and
Waanders, E., Keimpema, L. van, Brouwer, J.T., Oijen, M.G.H. van, Aerts, R., Sweep, C.G.J., Nevens, F., Drenth, J.P.H.   +7 more
openaire   +2 more sources

Relationship between serum calcium and CA 19-9 levels in colorectal cancer [PDF]

, 2004
AIM: To examine the calcium metabolism of colorectal cancer (CRC) in patients with colorectal cancer and control patients. METHODS: Seventy newly diagnosed CRC patients were included.
Fuszek, Péter, Horváth, Henrik Csaba, Lakatos, Péter, Lakatos, Péter László, Nagy, Zsolt, Papp, János, Speer, Gábor, Tabák, Ádám, Takács, István   +8 more
core   +1 more source

Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholagnitis [PDF]

, 2018
The non-invasive differentiation of malignant and benign biliary disease is a clinical challenge. Carbohydrate antigen 19-9 (CA19-9), leucine-rich α2-glycoprotein (LRG1), interleukin 6 (IL6), pyruvate kinase M2 (PKM2), cytokeratin 19 fragment (CYFRA21.1)
Blyuss, O, Cuenco, J, Dawnay, A, Kazarian, A, Manns, MP, Menon, U, Pereira, SP, Timms, JF, Wehnert, N, Whitwell, HJ   +9 more
core   +2 more sources

Hepatocellular Carcinoma Producing Carcinoembryonic Antigen and Carbohydrate Antigen 19-9.

Internal Medicine, 1992
A case of hepatocellular carcinoma producing carcinoembryonic antigen and carbohydrate antigen 19-9 is reported. The serum level of carcinoembryonic antigen was 26,800 ng/ml and carbohydrate antigen 19-9, 5,500 U/ml on the final day. Immunohistochemical study revealed positive monoclonal antibodies for these two antigens within the cytoplasm of the ...
Y, Usui, H, Miura, Y, Kimura, S, Takayama, M, Nakayama   +4 more
openaire   +3 more sources

Autoimmune pancreatitis associated with a pancreatic pseudocyst treated by distal pancreatectomy with splenectomy: case report [PDF]

, 2014
Autoimmune pancreatitis is a unique type of chronic pancreatitis, which is rarely associated with pseudocyst. A 48-year-old lady was admitted to our department with a rapidly growing cystic mass in the pancreatic tail with an elevated concentration of ...
Shu-Sen Zheng, Wei-Lin Wang, Xiao-Bo Xu, Ying-Shen Wu   +3 more
core   +1 more source

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer [PDF]

, 2013
AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer.
Bria, E., Cognetti, F., Gamucci, T., Gelibter, A., Mansueto, G., Milella, M., Moscetti, L., Ruggeri, E. M., Sperduti, I., Vaccaro, V.   +9 more
core   +1 more source